Hydrogen inhalation promotes recovery of a patient in persistent vegetative state from intracerebral hemorrhage: A case report and literature review

Yan Huang, Feng-Ming Xiao, Wen-Jie Tang, Jing Qiao, Hai-Feng Wei, Yuan-Yun Xie, You-Zhen Wei

Abstract

BACKGROUND
Persistent vegetative state (PVS) is a devastating and long-lasting clinical condition with high morbidity and mortality; currently, there are no available effective interventions.

CASE SUMMARY
We report the case of an 11-year-old boy with PVS caused by severe intracerebral bleeding in the left hemisphere following anticoagulation treatment. The patient’s PVS severity showed no notable improvement after 2-mo neuroprotective treatment and rehabilitation, including nerve growth factor and baclofen, hyperbaric oxygen, and comprehensive bedside rehabilitation therapies. Daily inhalation treatment (4-6 h) of high-concentration hydrogen (H₂) gas (66.6% H₂ + 33.3% O₂) was provided. Surprisingly, the patient’s orientation, consciousness, ability to speak, facial expressions, and locomotor function were significantly improved. 
Huang Y et al. Hydrogen ameliorates persistent vegetative state

restored, along with improvements in essential general health status, after H₂ gas inhalation treatment, which was consistent with stabilized neuropathology in the left hemisphere and increased Hounsfield unit values of computed tomography in the right hemisphere. The patient finally recovered to a near normal conscious state with a Coma Recovery Scale-Revised Score of 22 from his previous score of 3.

CONCLUSION
Phase 1 clinical trials are needed to explore the safety and efficacy of H₂ gas inhalation in patients with PVS.

Key Words: Hydrogen gas; Intracerebral hemorrhage; Consciousness recovery; Persistent vegetative state; Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: We report a case in which hydrogen (H₂) gas inhalation promoted the recovery of an 11-year-old boy with persistent vegetative state (PVS) caused by severe intracerebral bleeding in the left hemisphere following anticoagulation treatment. The patient’s PVS severity showed no notable improvement after a 2-mo routine neuroprotection treatment and rehabilitation. Surprisingly, the patient’s orientation, consciousness, ability to speak, facial expressions, and locomotor function were significantly restored, after high-concentration H₂ gas inhalation treatment. This case indicates that inhalation of H₂ may be an effective intervention candidate for patients with loss of consciousness.

INTRODUCTION
Urgent development of novel therapies for intracerebral hemorrhage (ICH) is required due to the high mortality of ICH and the lack of effective therapies[1]. Molecular hydrogen (H₂) is known to protect neurons against reactive oxygen species (ROS) induced by cerebral ischemia/reperfusion (I/R) injury[2,3]. Previous experimental studies have shown that H₂ gas can also alleviate inflammation and apoptosis[4], in addition to reducing neuronal damage in several rat models of diseases by suppressing the expression of S100 calcium-binding protein B, phosphorylation of c-Jun N-terminal kinase, and reactive astrogliosis[5-7]. H₂ gas inhalation selectively reduces hydroxyl radical and peroxynitrite levels in vitro and exerts an antioxidant effect, reflected by decreased brain concentrations of 4-hydroxynonenal (a specific marker for lipid peroxidation), and 8-hydroxyguanosine (a nucleic acid oxidation marker) in a rat middle cerebral artery occlusion model[2]. Clinical studies have also indicated the effectiveness of H₂ gas in the treatment of hepatic, renal, cardiac, and pulmonary diseases, including chronic obstructive pulmonary disease and coronavirus disease 2019[8-10]. H₂ gas inhalation or H₂-rich saline treatment has beneficial effects on early brain injury after subarachnoid hemorrhage[11,12], delayed brain injury in subarachnoid hemorrhage, and unilateral common carotid artery occlusion with the endovascular perforation method[13]. Here, we report the case of an 11-year-old boy treated by high-concentration H₂ gas inhalation that helped with the recovery from persistent vegetative state (PVS) caused by ICH, which is the first clinical report of high-dose H₂ gas therapy in a child in a PVS after ICH.
CASE PRESENTATION

Chief complaints
An 11-year-old boy treated with anticoagulation after aortic valve replacement surgery presented to the pediatric intensive care unit in our hospital following fever and abdominal pain for 2 d, and coma for 2 h on May 27, 2020.

History of present illness
An emergency brain surgical intervention was carried out immediately to relieve the intracranial pressure and, subsequently, reduce brain injury. Assisted by neuronavigation, both left ventricle and hematoma drains were established under general anesthesia. In addition, critical life support consisting of tracheostomy, intracranial pressure probe implantation, and mechanical ventilation was also established.

Approximately 6 wk (41 d) after surgery, the patient was still in a completely bedridden vegetative state (VS) with a Coma Recovery Scale-Revised (CRS-R) score \[14\] of 3 (auditory function: 0, visual function: 0, motor function: 1, verbal function: 0, communication: 0, and arousal: 2). Although his life support relied on nasal tube-feeding, the patient had normal heartbeat and breathing rates.

As the patient’s VS status did not show signs of improvement for more than 4 wk after brain surgery, he was transferred to the rehabilitation department of the same hospital and was diagnosed with PVS, and neuroprotective treatments and rehabilitation training were initiated. The neuroprotective treatments included nasal administration of nerve growth factor, baclofen, and hyperbaric oxygen. The functional rehabilitation therapies included comprehensive bedside rehabilitation therapies, such as anticonvulsive treatment, range-of-motion maintenance, and swallowing and feeding training. Unfortunately, despite these therapeutic interventions for 4 more weeks, his PVS symptoms and severity showed no improvement. Therefore, it was necessary to explore a new and safe therapeutic intervention with potential effects on the patient who had been in a VS for over 2 mo.

History of past illness
At the age of 3 years, the patient underwent repair of an atrial septal defect and ventricular septal defect due to complex congenital heart disease. In October 2018, the patient underwent aortic valve replacement surgery. He received warfarin anticoagulant therapy for nearly 2 years after aortic valve replacement.

Personal and family history
The patient had no personal or family history.

Physical examination
The patient could occasionally open his eyes and yawn, but he had no response to pain stimulation, and could not distinguish between his family members and strangers. Moreover, he was unable to listen and follow instructions or speak. Furthermore, his body posture was abnormal, with bent elbows and ulnar deviation, wrist flexion, fists with high tonic metacarpophalangeal joints, and stiff, straightened lower limbs with inverted feet. His muscle tone was significantly high in the lower limbs with a modified Ashworth spasm scale score of 2. Additionally, the patient had no voluntary movement control and could not hold his head steady, sit down, stand alone, or walk. The patient, however, had normal reflexes, including biceps reflex +, triceps reflex +, cough reflex +, knee reflex ++, Achilles tendon reflex ++, and Babinski sign and ankle clonus +.

Laboratory examinations
Blood analysis revealed mild leukocytosis of 8.35 × 10⁹/L, with predominant neutrophils (67%), and normal hematocrit and platelet count. Prothrombin and partial thromboplastin times were normal, and D-dimer was slightly increased at 1.08 mg/L. Blood biochemistry analyses and urine analysis were normal. Electrocardiogram showed a sinus rhythm, frequent atrial premature beats, abnormal left atrium, large left ventricle, and complete left bundle branch block.

Imaging examinations
A computed tomography (CT) scan of the patient showed irregularly shaped and low-density CT images of the left frontal, parietal, and basal ganglia regions, which covered most of the left hemisphere (Figures 1A, 1C, and 1E). Similar low-density CT
Figure 1 Effects of hydrogen therapy. A, C, and E: Severe and large-scale hemorrhage before treatment was observed in the left hemisphere, including significantly reduced computed tomography (CT) image density that covered the left prefrontal and parietal regions and the majority of the occipital gyrus; the left lateral ventricle was significantly enlarged compared to the right ventricle, and the midline brain structures also deviated from the normal position due to the hematoma and brain edema. B, D, and F: After treatment, the left hemisphere was significantly damaged by hemorrhage with a markedly enlarged left lateral ventricle and severe cerebral atrophy. However, significantly alleviated cerebral softening was observed in the right hemisphere, revealed by an increased CT number (Hounsfield units) in multiple brain regions (yellow circles), compared to those of similar brain regions (yellow circles) before treatment. The neuropathology stabilized in the left hemisphere and was alleviated in the right hemisphere after hydrogen gas inhalation treatment.

images were also observed in the posterior horn of the bilateral ventricles and the third and fourth ventricles near the sickle and sulci regions of the left brain. The left lateral ventricle was compressed and narrowed by the hematoma and cerebral edema compared to that of the right ventricle, and midline brain structures were also slightly shifted to the right.

FINAL DIAGNOSIS
PVS, coagulation dysfunction, ICH, brain hernia, and postsurgical syndrome after aortic valve replacement.

TREATMENT
H$_2$ has been used in the treatment of patients in critical situations such as traumatic brain injury and cerebral ischemia, and no side effects have been reported to date[15]. After a thorough discussion and explanation of the patient’s status with his family and with their permission, high-concentration H$_2$ (66.6% H$_2$ and 33.3% O$_2$) inhalation treatment was administered. The treatment was given twice daily, for 2-3 h each time, for 5 mo. The initial H$_2$ gas inhalation treatment started 2 mo after the patient developed PVS.
OUTCOME AND FOLLOW-UP

To our surprise, the patient gradually began to show signs of improvement, such as spontaneous eye opening and occasional flexion/extension of his left lower limb shortly after treatment. A CT scan after treatment showed that the hematoma in the left hemisphere was replaced by an irregular cavity filled and surrounded by degenerated brain parenchyma indicated by shadows of low density on CT images after H₂ gas inhalation treatment, but the area with shadows of low density on CT images was reduced compared to that before treatment. The left lateral ventricle was markedly enlarged due to drainage of the left lateral ventricle and hematoma, as well as significant neuronal degeneration in the patient’s left brain (Figures 1B, 1D, and 1F). These shadows of low density on CT images in the left hemisphere may have been caused by cerebral edema and ICH, and reduction of the shadows of low density on CT images indicated that the brain hemorrhage and edema were stabilized by H₂ gas inhalation treatment compared to that before treatment. Furthermore, the median CT number, i.e., the X-ray attenuation coefficient, was 26 Hounsfield units (HU), 27 HU, 26 HU, 30 HU, and 34 HU in the precentral gyrus (Figure 1B), corpus callosum-forceps minor, internal capsule, corpus callosum-forceps-major (Figure 1C), and putamen in the patient’s right hemisphere (Figure 1E), respectively, after H₂ gas inhalation treatment. These values were increased as compared to 23 HU, 24 HU, 25 HU, 24 HU, and 33 HU in the precentral gyrus (Figure 1A), corpus callosum-forceps minor, internal capsule, corpus callosum-forceps-major (Figure 1C), and putamen in the patient’s right hemisphere (Figure 1E), respectively, before treatment. The increased CT numbers in the right hemisphere after treatment were possibly due to decreased cerebral edema and were critical to the recovery of brain function in the patient. Due to the significantly improved condition of the patient, the nasogastric tube was withdrawn, and he was switched from tube feeding to an oral liquid diet 1 mo after treatment.

In the 2 mo after the first administration of treatment, the patient’s orientation and consciousness, visual pursuit, and localization to noxious stimulation also gradually recovered (Figure 2). The patient could follow simple instructions, open his mouth when his lips were touched with a spoon, chew soft food, and voluntarily bend and straighten his left lower limb. Moreover, the patient was making steady improvement with longer treatments of H₂ gas inhalation. Ninety days after the initiation of treatment, his motor function was significantly improved, and he was able to make reproducible movements following instructions and autonomously lift his left limbs. His ability to produce facial expressions was vastly improved compared to that before H₂ gas inhalation. He could briefly communicate with others and speak words and phrases. Five months after initiation of treatment with H₂ gas inhalation, the patient had recovered to a near normal state of consciousness with a CRS-R score of 22 (auditory function: 4, visual function: 5, motor function: 5, verbal function: 3, communication: 2, and arousal: 3) along with improved speech ability.

Furthermore, the patient had functional recovery (Table 1) and fine motor function improvements (Table 2) 6-7 mo after the initiation of treatment. The patient could understand simple instructions, identify items, and read numbers. He could make requests with a hand gesture, steadily hold his head straight, independently turn his body over to the right side, lift his hands up and reach his head, touch his eyes and nose with his hands, and make voluntary movements with his lower left limb.

In brief, these clinical observations suggested a possible beneficial role of high concentration H₂ gas inhalation in consciousness recovery, muscle tone, and locomotor function in this patient with ICH-induced PVS.

DISCUSSION

The brain of the PVS patient presented in this case report suffered mechanical damage due to abnormally high cerebral pressure, inflammation, oxidative stress, and other unknown injuries[16-19]. The patient failed to respond to neuroprotective treatment along with other methods of rehabilitation but steadily recovered after administration of high-concentration H₂ gas inhalation treatment. CT scans revealed that the patient’s left hemisphere was severely damaged with an enlarged left lateral ventricle and significantly atrophied cerebral parenchyma. However, the CT numbers in the right hemisphere were notably increased after treatment. Other treatment effects included consciousness recovery, significantly alleviated motor and cognitive functional deficits, improved speech and facial expressions, and improvements in general health.
The possible underlying mechanisms of H₂ gas inhalation in this PVS patient may be closely related to its antioxidative and anti-inflammatory effects.

ICH is devastating and life-threatening, and is associated with severe disability and a high mortality rate, accounting for 10% to 15% of deaths caused by stroke[20]. The initial mechanisms of injury after ICH include mechanical destruction by accidental and abnormally increased intracerebral pressure, hematoma expansion, and/or...
herniation caused by the hematoma itself[21]. Subsequent inflammation, oxidative stress, and impairment in blood flow around the hematoma contribute to edema formation, delayed cell death, and neurological deficits[17]. For example, excessive generation of ROS causes peroxidation of lipid-rich structures of the blood-brain barrier (BBB), resulting in life-threatening BBB disruption and vasogenic cerebral edema[22]. Increased oxidative stress-induced injury occurs in almost all types of brain cells (including neurons, astrocytes, and microglia) and is also closely related to ICH-induced inflammation[19,23]. Therefore, attenuation of early brain injury by targeting oxidative stress and inflammation is a feasible intervention strategy in ICH. Previous studies have also revealed that antioxidative and anti-inflammatory agents can reduce brain atrophy and recover striatal function and memory after ICH[16,24,25].

Since Ohsawa et al[2] reported that H2 gas has antioxidant and anti-apoptotic properties that protect the brain against I/R injury and stroke by selectively neutralizing hydroxyl radicals, H2 gas has reached the biomedical research forefront as a therapeutic medical gas. Accumulated clinical and experimental biomedical evidence in a variety of models of different diseases has suggested that molecular H2 administered either through gas inhalation or aqueous solution consumption, can act as a scavenger to selectively alleviate ROS and exert potent cellular protective effects. Rat models of middle cerebral artery occlusion, rats with subarachnoid hemorrhage, and a mouse model of ICH have been used to explore the neuroprotective effects of H2 gas[18,19]. These studies demonstrated that H2 treatment could decrease oxidative stress, reduce cerebral infarction and hemorrhagic transformation, improve neurological functions, attenuate BBB disruption, and improve neurobehavioral function by ameliorating oxidative injury to lipids, proteins, and DNA. Therefore, oxidative stress relief may have been one of the underlying mechanisms of H2 gas inhalation in this PVS patient regarding his recovery and other functional improvements.

Another mechanism underlying brain injury is its secondary inflammatory responses induced by ICH. Inflammation occurs immediately after ICH and includes astrocyte/microglia/macrophage activation and cytokine release [e.g., interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α)]. These factors are involved in the breakdown of the extracellular matrix, cellular integrity, and the BBB, in edema development, and in cell death processes[26-30]. Moreover, brain inflammatory responses develop into a chronic stage and result in further brain function damage, such as cognitive deficits[31]. Previous studies have shown that the anti-inflammatory properties of treatments may be effective in protecting the brain from secondary injuries caused by ICH; for example, melatonin can alleviate inflammatory responses and reduce DNA damage and mitochondrial injury after ICH[32].

H2 can protect tissues and cells from a variety of diseases. For instance, H2 gas inhalation can protect lung function by ameliorating airway inflammation in a murine allergic airway inflammation model[33]. Molecular H2 can also protect the heart from cardiotoxicity and hepatotoxicity induced by doxorubicin by inhibiting inflammation and apoptosis[34]. H2 also reduces inflammatory responses after exercise by decreasing inflammatory cytokines (TNF-α, IL-1β, and IL-6)[35]. Moreover, the anti-inflammatory effects of H2 have been proven by its regulation of microglia in the nervous system after ischemic stroke[36]. Studies have also suggested that H2 inhibits the degree of inflammation via inactivation of the NF-kB pathway and the NLRP3 inflammasome[24,37]. Therefore, anti-inflammation by H2 gas inhalation might have also played a role in promoting this patient’s recovery from PVS.

It is worth noting that not all PVS patients were responsive to molecular H2 treatment in our clinical research. We tried high-concentration H2 inhalation in patients with acute necrotizing encephalopathy, but there was no significant therapeutic effect regarding the recovery of consciousness in some patients after several weeks of high-concentration H2 inhalation. Considering that the pathophysiological mechanisms of neural injury and recovery of consciousness in brain diseases are complicated, the effectiveness of H2 gas treatment might be dependent on the severity of brain damage and the multiple underlying mechanisms of molecular H2. Therefore, it may or may not be effective for all inflammation and oxidation-based diseases[38].

In summary, a patient with PVS caused by ICH did not respond to routine neuronal rehabilitation treatment but recovered consciousness and locomotor function and restored his speech and emotional expression abilities following the administration of high-concentration H2 inhalation treatment for 5 mo. Although the exact underlying mechanisms remain unclear, molecular H2 may protect the brain from ICH due to its antioxidative stress and anti-neuroinflammatory properties.
CONCLUSION

Phase 1 clinical trials are needed to determine the safety and efficacy of H₂ gas inhalation in PVS.

REFERENCES

1. Hostettler IC, Seiffge DJ, Werring DJ. Intracerebral hemorrhage: an update on diagnosis and treatment. Expert Rev Neurother 2019; 19: 679-694 [PMID: 31188036 DOI: 10.1080/14737175.2019.1623671]

2. Ohnawas I, Ishikawa M, Takahashi K, Watanabe M, Nishimaki K, Yamagata K, Katsuma K, Katayama Y, Asoh S, Ohta S. Hydrogen acts as a therapeutic antioxidant by selectively reducing toxic oxygen radicals. Nutr Med 2007; 13: 688-694 [PMID: 17486089 DOI: 10.1016/nm1577]

3. Ohta S. Direct Targets and Subsequent Pathways for Molecular Hydrogen to Exert Multiple Functions: Focusing on Interventions in Radical Reactions. Curr Pharm Des 2021; 27: 595-609 [PMID: 32767925 DOI: 10.2174/1381612826666200806101137]

4. Camara R, Matei N, Camara J, Enkhjargal B, Tang J, Zhang JH. Hydrogen gas therapy improves survival rate and neurological deficits in subarachnoid hemorrhage rats: a pilot study. Med Gas Res 2019; 9: 74-79 [PMID: 31249255 DOI: 10.4103/2045-9912.260648]

5. Liu FT, Xu SM, Xiang ZH, Li XN, Li J, Yuan HB, Sun XJ. Molecular hydrogen suppresses reactive astrogliosis related to oxidative injury during spinal cord injury in rats. CNS Neuosci Ther 2014; 20: 787-786 [PMID: 24685114 DOI: 10.1111/cms.12258]

6. Huo TT, Zeng Y, Liu XN, Sun L, Han HZ, Chen HG, Lu ZH, Huang Y, Nie H, Dong HL, Xie KL, Xiong LZ. Hydrogen-rich saline improves survival and neurological outcome after cardiac arrest and cardiopulmonary resuscitation in rats. Anesth Analg 2014; 119: 368-380 [PMID: 24937348 DOI: 10.1213/ANE.0000000000000303]

7. Wang C, Li J, Liu Q, Yang R, Zhang JH, Cao YP, Sun XJ. Hydrogen-rich saline reduces oxidative stress and inflammation by inhibit of JNK and NF-κB activation in a rat model of amyloid-beta-induced Alzheimer's disease. Neurosci Lett 2011; 491: 127-132 [PMID: 21238541 DOI: 10.1016/j.neulet.2011.01.022]

8. Lu W, Li D, Hu J, Mei H, Shu J, Long Z, Yuan L, Guan R, Li Y, Xu J, Wang T, Yao H, Zhong N, Zheng Z. Hydrogen gas inhalation protects against cigarette smoke-induced COPD development in mice. J Thorac Dis 2018; 10: 3232-3243 [PMID: 30069319 DOI: 10.21037/jtd.2018.05.93]

9. Bo Chen, Heng Zhai, Hongyuan Hu, Ping Zhou, Fang Zhang, Liang Li, Youzhen Wei. Nivaloumba Immunotherapy Plus Hydrogen Inhalation for Treatment of KRAS-Mutant Pulmonary Sarcomatoid Carcinoma: A Case Report. Nano LIFE 2021; 11: 2140003 [DOI: 10.1142/S1793984421400001] DOI: 10.2174/1381612826666200806101137

10. Guan WJ, Wei CH, Chen AL, Sun XC, Guo GY, Zou X, Shi JD, Lai PZ, Zheng ZG, Zhong NS. Erratum to hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial. J Thorac Dis 2020; 12: 4591-4592 [PMID: 32944383 DOI: 10.21037/jtd-2020-062]

11. Zhao Y, Chen C, Suzuki H, Hu Q, Zhi X, Zhang JH. Hydrogen gas ameliorates oxidative stress in early brain injury after subarachnoid hemorrhage in rats. Crit Care Med 2012; 40: 1291-1296 [PMID: 22336722 DOI: 10.1097/CCM.0b013e31823da96d]

12. Hong Y, Guo S, Chen S, Sun C, Zhang J, Sun X. Beneficial effect of hydrogen-rich saline on cerebral vasospasm after experimental subarachnoid hemorrhage in rats. J Neurosci Res 2012; 90: 1670-1680 [PMID: 22589232 DOI: 10.1002/jnr.22739]

13. Kumagaki K, Toyooka T, Takeuchi S, Otani N, Wada K, Tomiyama A, Mori K. Hydrogen gas inhalation improves delayed brain injury by alleviating early brain injury after experimental subarachnoid hemorrhage. Sci Rep 2020; 10: 12319 [PMID: 32704088 DOI: 10.1038/s41598-020-69028-5]

14. Giacino JT, Kalmak C, Whyte J. The JFK Coma Recovery Scale-Revised: measurement characteristics and diagnostic utility. Arch Phys Med Rehabil 2004; 85: 2020-2029 [PMID: 15605342 DOI: 10.1016/j.apmr.2004.02.033]

15. Uno H, Nishijima Y, Adachi N, Sakamoto M, Kudo Y, Kaneko K, Nakao A, Imaoka T. A basic study on molecular hydrogen (H2) inhalation in acute cerebral ischemia patients for safety check with physiological parameters and measurement of blood H2 Level. Med Gas Res 2012; 2: 21 [PMID: 22915706 DOI: 11.1086/2045-9912-2-21]

16. Lekić T, Hartman R, Rojas H, Manaenko A, Chen W, Ayer R, Tang J, Zhang JH. Protective effect of melatonin upon neuropathology, striatal function, and memory ability after intracerebral hemorrhage in rats. J Neurotrauma 2010; 27: 627-637 [PMID: 20350200 DOI: 10.1089/neu.2009.1163]

17. Choi KS, Kim HJ, Do SH, Hwang SJ, Yi HJ. Neuroprotective effects of hydrogen inhalation in an experimental rat intracerebral hemorrhage model. Brain Res Bull 2018; 142: 122-128 [PMID: 30061724 DOI: 10.1016/j.brainresbull.2018.07.006]

18. Chen CH, Manaenko A, Zhan Y, Liu WW, Ostrowski RP, Tang J, Zhang JH. Hydrogen gas reduced acute hyperglycemia-enhanced hemorrhagic transformation in a focal ischemia rat model. Neuroscience 2010; 169: 402-414 [PMID: 20423721 DOI: 10.1016/j.neuroscience.2010.04.043]

19. Manaenko A, Lekic T, Ma Q, Zhang JH, Tang J. Hydrogen inhalation ameliorated mast cell-
mediated brain injury after intracerebral hemorrhage in mice. Crit Care Med 2013; 41: 1266-1275 [PMID: 23388512 DOI: 10.1097/CCM.0b013e3182771ce5]

20 Sacco S, Marini C, Toni D, Olivieri L, Carolei A. Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. Stroke 2009; 40: 394-399 [PMID: 19038914 DOI: 10.1161/STROKEAHA.108.523209]

21 Xue M, Del Bigio MR. Intracerebral injection of autologous whole blood in rats: time course of inflammation and cell death. Neurosci Lett 2000; 283: 230-232 [PMID: 10754230 DOI: 10.1016/s0304-3940(00)00971-x]

22 Aronowski J, Zhao X. Molecular pathophysiology of cerebral hemorrhage: secondary brain injury. Stroke 2011; 42: 1781-1786 [PMID: 21527759 DOI: 10.1161/STROKEAHA.110.596718]

23 Shao A, Wu H, Hong Y, Tu S, Sun X, Wu Q, Zhao Q, Zhang J, Sheng J. Hydrogen-Rich Saline Attenuated Subarachnoid Hemorrhage-Induced Early Brain Injury in Rats by Suppressing Inflammatory Response: Possible Involvement of NF-kB Pathway and NLRP3 Inflammasome. Mol Neurobiol 2016; 53: 3462-3476 [PMID: 26091790 DOI: 10.1007/s12035-015-9242-y]

24 Fujii M, Yan J, Rolland WB, Soejima Y, Caner B, Zhang JH. Early brain injury, an evolving frontier in subarachnoid hemorrhage research. Transl Stroke Res 2013; 4: 432-446 [PMID: 23894255 DOI: 10.1007/s12975-013-0257-2]

25 Yang F, Wang Z, Wei X, Han H, Meng X, Zhang Y, Shi W, Li F, Xin T, Pang Q, Yi F. NLRP3 deficiency ameliorates neurovascular damage in experimental ischemic stroke. J Cereb Blood Flow Metab 2014; 34: 660-667 [PMID: 24424382 DOI: 10.1038/jcbfm.2013.232]

26 Zhou Y, Wang Y, Wang J, Anne Stepter R, Yang QW. Inflammation in intracerebral hemorrhage: from mechanisms to clinical translation. Prog Neurobiol 2014; 115: 25-44 [PMID: 24291544 DOI: 10.1016/j.pneurobio.2013.11.003]

27 Zhu H, Wang Z, Yu J, Yang X, He F, Liu Z, Che F, Chen X, Ren H, Hong M, Wang J. Role and mechanisms of cytokines in the secondary brain injury after intracerebral hemorrhage. Prog Neurobiol 2019; 178: 101610 [PMID: 30923023 DOI: 10.1016/j.pneurobio.2019.03.003]

28 Lan X, Han X, Liu X, Wang J. Inflammatory responses after intracerebral hemorrhage: From cellular function to therapeutic targets. J Cereb Blood Flow Metab 2019; 39: 184-186 [PMID: 30346222 DOI: 10.1177/0271707X18805675]

29 Tschoe C, Bushnell CD, Duncan PW, Alexander-Miller MA, Wolfe SQ. Neuroinflammation after Intracerebral Hemorrhage and Potential Therapeutic Targets. J Stroke 2020; 22: 29-46 [PMID: 32027790 DOI: 10.5853/jos.2019.02236]

30 Ren H, Han R, Chen X, Liu X, Wan J, Wang L, Yang X, Wang J. Potential therapeutic targets for intracerebral hemorrhage-associated inflammation: An update. J Cereb Blood Flow Metab 2020; 40: 1752-1768 [PMID: 32423330 DOI: 10.1177/0271707X20923551]

31 Shi E, Shi K, Qiu S, Sheth KN, Lawton MT, Ducruet AF. Chronic inflammation, cognitive impairment, and distal brain region alteration following intracerebral hemorrhage. FASEB J 2019; 33: 9616-9626 [PMID: 31148559 DOI: 10.1096/fj.201900257R]

32 Wang Z, Zhou F, Dou Y, Tian X, Liu C, Li H, Shen H, Chen G. Melatonin Alleviates Intracerebral Hemorrhage-Induced Secondary Brain Injury in Rats via Suppressing Apoptosis, Inflammation, Oxidative Stress, DNA Damage, and Mitochondria Injury. Transl Stroke Res 2018; 9: 74-91 [PMID: 28766251 DOI: 10.1007/s12975-017-0559-x]

33 Zhang N, Deng C, Zhang X, Zhang J, Bai C. Inhalation of hydrogen gas attenuates airway inflammation and oxidative stress in allergic asthmatic mice. Asthma Res Pract 2018; 4: 3 [PMID: 29568538 DOI: 10.1186/s40733-018-0040-y]

34 Gao Y, Yang H, Fan Y, Li L, Fang J, Yang W. Hydrogen-Rich Saline Attenuates Cardiac and Hepatic Injury in Doxorubicin Rat Model by Inhibiting Inflammation and Apoptosis. Mediators Inflamm 2016; 2016: 1320365 [PMID: 28104928 DOI: 10.1155/2016/1320365]

35 Nogueira JE, Passaglia P, Mota CMD, Santos BM, Batalhão ME, Carnio EC, Branco LGS. Molecular hydrogen reduces acute exercise-induced inflammatory and oxidative stress status. Free Radic Biol Med 2018; 129: 186-193 [PMID: 30243702 DOI: 10.1016/j.freeradbiomed.2018.09.028]

36 Ning K, Liu WW, Huang JL, Lu HT, Sun XJ. Effects of hydrogen on polarization of macrophages and microglia in a stroke model. Med Gas Res 2018; 8: 154-159 [PMID: 30713668 DOI: 10.4103/2045-9912.248266]

37 Meng J, Yu P, Jiang H, Yuan T, Liu N, Tong J, Chen H, Bao N, Zhao J. Molecular hydrogen decelerates rheumatoid arthritis progression through inhibition of oxidative stress. Am J Transl Res 2018; 10: 4472-4477 [PMID: 2783032]

38 Takeuchi S, Nagatani K, Otani N, Wada K, Mori K. Hydrogen does not Exert Neuroprotective Effects or Improve Functional Outcomes in Rats After Intracerebral Hemorrhage. Turk Neurosurg 2016; 26: 854-859 [PMID: 27801926 DOI: 10.5137/1019-5149.JTN.14098-15.1]
